We are live on ! Find out more
IMMX icon

Immix Biopharma
IMMX

28 hedge funds and large institutions have $5.43M invested in Immix Biopharma in 2023 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,200% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 1

292% more capital invested

Capital invested by funds: $1.39M → $5.43M (+$4.04M)

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

75% more funds holding

Funds holding: 16 → 28 (+12)

1.96% more ownership

Funds ownership: 2.06% → 4.02% (+2%)

Holders
28
Holders Change
+12
Holders Change %
+75%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
7
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EI
EAM Investors
California
+$465K
2
PAG
Private Advisor Group
New Jersey
+$452K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$245K
4
Renaissance Technologies
Renaissance Technologies
New York
+$147K
5
Morgan Stanley
Morgan Stanley
New York
+$145K

Top Sellers

Rank Fund Capital Flow
1
Koshinski Asset Management
Koshinski Asset Management
Illinois
-$174K
2
ICG
InterOcean Capital Group
Tennessee
-$18.1K
3
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$2.51K
4
BlackRock
BlackRock
New York
-$1.26K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.11M +$245K +54,188 +51%
EI
2
EAM Investors
California
$710K +$465K +102,661 New
PAG
3
Private Advisor Group
New Jersey
$690K +$452K +99,775 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$577K +$47.1K +10,405 +14%
State Street
5
State Street
Massachusetts
$297K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$224K +$147K +32,400 New
Morgan Stanley
7
Morgan Stanley
New York
$224K +$145K +31,936 +7,984%
Commonwealth Equity Services
8
Commonwealth Equity Services
Massachusetts
$196K -$2.51K -555 -2%
Northern Trust
9
Northern Trust
Illinois
$169K +$110K +24,378 New
IW
10
Imprint Wealth
South Carolina
$143K +$51.6K +11,400 +49%
MAWA
11
Moss Adams Wealth Advisors
Washington
$138K – – –
TAM
12
Tocqueville Asset Management
New York
$138K +$36.2K +8,000 +67%
JF
13
Jump Financial
Illinois
$128K +$83.8K +18,500 New
BlackRock
14
BlackRock
New York
$123K -$1.26K -279 -2%
Jane Street
15
Jane Street
New York
$103K +$67.6K +14,922 New
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$99.3K +$65K +14,351 New
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$82.5K – – –
ICG
18
InterOcean Capital Group
Tennessee
$82.3K -$18.1K -4,000 -25%
Bank of Montreal
19
Bank of Montreal
Ontario, Canada
$72K +$45.3K +10,000 New
ONB
20
Old National Bancorp
Indiana
$69.2K +$45.3K +10,000 New
UBS Group
21
UBS Group
Switzerland
$18.2K +$11.9K +2,628 New
Bank of America
22
Bank of America
North Carolina
$11K +$7.22K +1,594 New
TIM
23
Tortoise Investment Management
New York
$9K – – –
JP Morgan Chase
24
JP Morgan Chase
New York
$4.69K +$3.04K +671 +9,586%
TRCT
25
Tower Research Capital (TRC)
New York
$3.99K +$2.61K +577 New
1
2

IMMX Hedge Fund Activity: Q4 2023 in Review

28 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q4 2023, worth a combined $5.43M — up 292% from $1.39M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new IMMX positions and 1 closed out — a net gain of 12 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was EAM Investors, opening a new position worth an estimated $465K. The largest seller was Koshinski Asset Management, exiting entirely with an estimated $174K sold.

  • 28 institutional investors held Immix Biopharma (IMMX) as of Q4 2023, up from 16 in Q3 2023.
  • Funds reported $5.43M of Immix Biopharma stock for Q4 2023, up 292% quarter-over-quarter.
  • 13 funds opened new Immix Biopharma positions in Q4 2023 and 1 closed out, a net change of +12 holders.
  • The largest Immix Biopharma buyer in Q4 2023 was EAM Investors, an estimated $465K added.
  • The largest Immix Biopharma seller in Q4 2023 was Koshinski Asset Management, an estimated $174K sold.

Based on aggregated 13F filings for Q4 2023.